Amgen's Obesity Drug Hype Meets the Reality of a Sequential Earnings Decline

Amgen Inc. (AMGN) reports first-quarter 2026 earnings after the close on April 30, 2026, with analysts expecting $4.73 per share—a year-over-year decline that marks a notable shift for the biotech giant. The central question: can Amgen's diversified portfolio of blockbuster drugs and emerging franchises offset biosimilar headwinds and pricing pressures that have weighed on near-term estimates? With the stock trading at $338.02 and technical momentum weakening into the print, investors will scrutinize whether management can reaffirm full-year guidance and demonstrate that its six priority growth drivers can sustain the double-digit expansion delivered in 2025.

Part 1: Earnings Preview

Amgen Inc. is one of the world's leading biotechnology companies, focused on discovering, developing, and commercializing innovative human therapeutics across oncology, cardiovascular disease, bone health, and rare diseases. Its portfolio includes established blockbusters like Enbrel, Prolia, and Repatha, alongside a growing biosimilars franchise and next-generation pipeline assets.

Amgen reports first-quarter 2026 earnings after market close on April 30, 2026. The consensus estimate stands at $4.73 per share, with no revenue estimate provided in the data. The company most recently reported $5.29 per share for the fourth quarter of 2025. Comparing the Q1 2026 estimate to the same quarter last year—when Amgen delivered $4.90 per share—reveals an expected 3.47% year-over-year decline, a notable reversal after four consecutive quarters of double-digit earnings beats.

Three key themes define this earnings story:

1. Biosimilar Competition and Patent Cliff Pressures: Amgen faces intensifying biosimilar competition across legacy franchises, particularly in oncology and immunology, while navigating pricing headwinds in the U.S. and Europe. Investors will watch for commentary on how the company is managing volume declines and whether its own biosimilars business (which delivered $3.0 billion in 2025) can offset erosion in originator products. The lower year-over-year EPS estimate suggests analysts are pricing in near-term margin compression from these dynamics.

2. Growth Driver Momentum—Repatha, Evenity, and Rare Disease: Management has identified six priority growth drivers expected to more than offset legacy product declines: Repatha (cardiovascular), Evenity (bone health), Tespire (respiratory), rare disease assets, innovative oncology, and biosimilars. Repatha's 36% growth in 2025 to over $3 billion, bolstered by positive Vesalius CV Phase III data showing a 25% reduction in major cardiovascular events, positions it as a key upside catalyst. Evenity's 34% growth to $2.1 billion and the rare disease portfolio's 14% expansion to $5.2 billion demonstrate breadth, but investors need confirmation that this momentum is accelerating into 2026 despite seasonal insurance headwinds flagged by management.

3. Pipeline Progress and R&D Investment Payoff: Amgen's record $7.2 billion R&D spend in 2025 (up 22%) reflects aggressive investment in late-stage programs, including six global Phase III trials for obesity candidate Meritide, the OCEAN-A outcome study for olpasiran, and multiple bispecific T-cell engager programs. However, the company also announced significant setbacks in Q4 2025, including a regulatory action on Tavneos and slower-than-expected event accrual for olpasiran. Investors will scrutinize pipeline updates for evidence that the elevated R&D spend is translating into near-term commercial opportunities, particularly as the company prepares manufacturing capacity for Meritide.

Analyst commentary ahead of the release reflects cautious optimism tempered by near-term headwinds. The consensus has drifted lower over the past 90 days, with the Q1 estimate declining from $5.11 to $4.73, suggesting analysts are incorporating weaker-than-expected seasonal dynamics and biosimilar pressure. However, the full-year 2026 estimate of $22.16 implies only modest growth, and several analysts have noted that Amgen's guidance for a "lower mid-single-digit year-over-year revenue decline in Q1" and the lowest operating margin of the year sets a low bar for the company to clear. The key will be whether management reaffirms its full-year revenue guidance of $37.0–$38.4 billion and non-GAAP EPS of $21.60–$23.00, and whether commentary on Repatha, Meritide, and biosimilars can offset concerns about the Tavneos setback and slower olpasiran progress.

Part 2: Historical Earnings Performance

Amgen has delivered a remarkably consistent pattern of earnings beats over the past four quarters, with reported EPS exceeding estimates by double-digit percentages in every release. The most recent quarter (December 2025) saw the company report $5.29 against a $4.76 estimate, a +11.13% surprise. This followed September 2025's $5.64 versus $5.00 estimate (+12.80% surprise), June 2025's $6.02 versus $5.26 estimate (+14.45% surprise), and March 2025's $4.90 versus $4.16 estimate (+17.79% surprise). The magnitude of these beats has been substantial, ranging from $0.53 to $0.76 per share.

The trend shows beats are becoming slightly smaller in percentage terms—from +17.79% four quarters ago to +11.13% most recently—but remain well above typical biotech sector beat rates. Notably, the absolute dollar beats have also compressed from $0.74–$0.76 in the middle two quarters to $0.53 in Q4 2025, suggesting either that analysts are catching up to the company's operational momentum or that underlying business trends are moderating. The June 2025 quarter stands out with the highest absolute EPS of $6.02, reflecting what management described as broad commercial momentum across 14 blockbuster products.

For the upcoming Q1 2026 report, the $4.73 consensus estimate sits $0.17 below the $4.90 reported in the same quarter last year, implying a -3.47% year-over-year decline. This represents a notable departure from the growth trajectory of recent quarters and suggests analysts are building in caution around seasonal headwinds, biosimilar competition, and the lower operating margin guidance management provided for Q1. However, given Amgen's four-quarter streak of double-digit beats and management's track record of conservative guidance, the company has established a pattern of exceeding lowered expectations—the question is whether the magnitude of any beat will satisfy investors given the stock's recent technical weakness.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Amgen typically reports earnings after market close, meaning Day 0 reflects anticipatory trading before results are released, while Day +1 captures the market's first full session to react to actual numbers and management commentary.

The historical data reveals substantial volatility around Amgen earnings, with Day +1 moves averaging 5.85% in absolute terms and ranging as high as 11.82% (May 2024). The most recent four quarters show a clear pattern: three of the four Day +1 sessions produced gains of 6.50% or more (February 2025: +6.50%, November 2025: +7.81%, February 2026: +8.15%), while August 2025 saw a -5.14% decline despite the company beating estimates. This suggests the market rewards strong beats and positive guidance with outsized moves, but punishes any disappointment or cautious commentary even when headline numbers exceed expectations.

The Day 0 moves have been relatively muted, averaging just 0.84%, with the largest pre-announcement move being -2.45% in May 2025. This indicates limited information leakage and suggests most of the price discovery occurs after results and guidance are disclosed. The average Day +1 range of 5.64% closely matches the average absolute move of 5.85%, indicating directional conviction once the market digests the full picture. Given the current setup—where estimates have been lowered, technical momentum is weakening, and the stock sits below most key moving averages—investors should prepare for a potentially volatile reaction. A beat accompanied by reaffirmed full-year guidance could trigger a 6–8% rally similar to recent positive reactions, while any miss or guidance cut could produce a sharp decline given the stock's already fragile technical position.

Part 2.2: Options Market Expected Move

The options market is pricing a 3.70% expected move (±$12.52, range $325.50–$350.54) for the May 1, 2026 weekly expiration, which is notably lower than the 5.85% average absolute Day +1 move observed over the past eight quarters. This suggests options traders are either underpricing potential volatility or expecting a more muted reaction than history would indicate—possibly reflecting the lowered estimate bar and reduced conviction heading into the print. Investors considering options strategies should note that historical moves have exceeded the current implied move in five of the past eight earnings events, with the most recent three quarters all producing Day +1 moves of 5.14% or greater.

Part 3: What Analysts Are Saying

Analyst sentiment on Amgen reflects moderate optimism with a cautious undertone, as the consensus rating stands at 3.64 on the 5-point scale—solidly in "Hold" territory but leaning toward "Buy." Of the 36 analysts covering the stock, 13 rate it a Strong Buy and 2 a Moderate Buy, while 18 assign a Hold rating. The bear case is represented by 1 Moderate Sell and 2 Strong Sells. The average price target of $357.84 implies 5.9% upside from the current price of $338.02, though the wide range—from a low of $200.00 to a high of $432.00—reflects significant disagreement about the company's trajectory.

Sentiment has deteriorated over the past month, with the average recommendation slipping from 3.66 to 3.64 and one analyst downgrading from Hold to a more cautious stance. This modest weakening coincides with the stock's technical deterioration and suggests some analysts are growing concerned about near-term headwinds, particularly around biosimilar competition, the Tavneos regulatory setback, and slower-than-expected progress on the olpasiran outcome study. The fact that the Hold camp has grown from 17 to 18 analysts over the past month—while Strong Buy and Moderate Buy counts remained flat—indicates a shift toward wait-and-see positioning ahead of the Q1 report.

The $357.84 consensus target sits roughly 6% above current levels, a relatively modest premium that suggests analysts are pricing in limited near-term upside even if the company meets expectations. However, the high-end target of $432.00 implies 27.8% upside for bulls who believe Amgen's growth drivers can accelerate and pipeline assets can offset legacy product erosion. Conversely, the $200.00 low-end target—40.8% below current levels—reflects deep skepticism about the company's ability to navigate patent cliffs and competitive pressures. The upcoming earnings report will be critical in determining whether the consensus gravitates toward the bullish or bearish end of this range, particularly if management provides updated guidance on Repatha's trajectory, Meritide's commercial timeline, and the impact of biosimilar competition on 2026 margins.

Part 4: Technical Picture

Amgen's technical setup heading into earnings has deteriorated sharply, with the Barchart Technical Opinion registering just 8% Buy—down from 24% a week ago and 40% a month ago. This collapse in technical strength reflects a stock under sustained selling pressure, with momentum indicators flashing caution as the company approaches a critical earnings catalyst. The signal remains nominally in "Buy" territory but at such a weak level that it offers little support for bulls.

Timeframe Analysis:

• Short-term (50% Sell): Moderate sell signal indicates near-term momentum has turned negative, with the stock failing to hold recent support levels
• Medium-term (50% Buy): Neutral-to-slightly-bullish reading suggests the intermediate trend remains intact despite recent weakness, though conviction is fading
• Long-term (50% Buy): Moderate buy signal reflects the stock's position above the 200-day moving average, preserving the longer-term uptrend structure

Trend Characteristics: The overall trend is characterized as Weak and Weakening, indicating that while the stock hasn't broken down completely, momentum is deteriorating across timeframes and the path of least resistance is lower absent a strong earnings catalyst.

The stock currently trades at $338.02, positioned below the 5-day ($342.19), 10-day ($345.66), 20-day ($347.29), 50-day ($359.29), and 100-day ($348.93) moving averages, but above the 200-day moving average ($324.45). This configuration—where the stock sits beneath all short- and intermediate-term averages but above the long-term trend line—is classic pre-earnings vulnerability. The 50-day moving average at $359.29 represents the most significant overhead resistance, sitting 6.3% above current levels and roughly in line with the consensus analyst price target.

The $324.45 level (200-day moving average) emerges as the critical support to watch—a break below would signal a broader trend reversal and likely trigger additional technical selling. On the upside, reclaiming the 20-day moving average at $347.29 would be the first step toward repairing the technical damage, with the 50-day at $359.29 representing the key resistance that would need to be cleared to confirm renewed bullish momentum. The overall setup is cautionary heading into earnings: the stock has lost its short-term footing, sits in a vulnerable position relative to key moving averages, and shows weakening momentum across all timeframes. A strong beat with reaffirmed guidance could provide the catalyst needed to reverse this technical deterioration, but any disappointment risks accelerating the decline toward the 200-day support. Given the 3.70% options-implied move and the stock's historical tendency to produce 5–8% post-earnings swings, traders should expect heightened volatility and be prepared for a decisive break in either direction.